Biblio Discovery — Demo Discovery Service

6 results for "Patrick Most"

Showing 1–6 · 0.26 seconds · RSS

  1. Journal Article Full text

    MicroRNA-138 Regulates Hypoxia-Induced Endothelial Cell Dysfunction By Targeting S100A1

    Anagha Sen; Shumei Ren; Carolin Lerchenmüller et al.

    PLoS ONE, Vol. 8 No. 11 · 2013 · English · PLOS Scopus

    The Ca2+ sensor S100A1 is essential for proper endothelial cell (EC) nitric oxide (NO) synthase (eNOS) activation. S100A1 levels are greatly reduced in primary human microvascular ECs subjected to hypoxia, rendering them dysfunctional. However mechanisms that regulate S100A1 levels in ECs are…

  2. Journal Article Full text

    CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression

    Henrike Tscheschner; Eric Meinhardt; Philipp Schlegel et al.

    PLOS ONE, Vol. 14 No. 4 · 2019 · English · PLOS Scopus

    …like the activation of CaMKII, phospholamban (PLN) and p53 accumulation. Most importantly, cardiac GRP78 gene therapy in mice treated with Dox revealed improved diastolic function (dP/dtmin) and survival after Dox treatment. In conclusion, our results demonstrate for the first time that Ca2+…

  3. Journal Article Full text

    G protein-coupled receptor kinase 2 promotes cardiac hypertrophy

    Philipp Schlegel; Julia Reinkober; Eric Meinhardt et al.

    PLOS ONE, Vol. 12 No. 7 · 2017 · English · PLOS Scopus

    The increase in protein activity and upregulation of G-protein coupled receptor kinase 2 (GRK2) is a hallmark of cardiac stress and heart failure. Inhibition of GRK2 improved cardiac function and survival and diminished cardiac remodeling in various animal heart failure models. The aim of the…

  4. Journal Article Full text

    Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology

    Claire Verkuyl; Ari Belotserkovsky; Thomas Zerbes et al.

    PLOS One, Vol. 20 No. 11 · 2025 · English · PLOS Scopus

    Any strategy that can selectively and persistently lower the brain levels of the cellular prion protein (PrPC) is expected to extend survival in prion diseases. Recent advances in the virus-mediated delivery of gene therapies prompted us to explore if a recombinant adeno-associated virus (rAAV)…